Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw |
Kim, Yun-Ho
(Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University)
Park, Han-Kyul (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) Choi, Na-Rae (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) Kim, Seong-Won (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) Kim, Gyoo-Cheon (Department of Oral Anatomy, School of Dentistry, Pusan National University) Hwang, Dae-Seok (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) Kim, Yong-Deok (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) Shin, Sang-Hun (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) Kim, Uk-Kyu (Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University) |
1 | Lee JK, Kim KW, Choi JY, Moon SY, Kim SG, Kim CH, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg 2013;39:9-13. DOI |
2 | Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee [Internet]. Silver Spring (MD): US Food and Drug Administration; 2011 [cited 2016 Aug 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf. |
3 | Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. DOI |
4 | Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 2013;61:33-8. |
5 | Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. DOI |
6 | Song JW, Kim KH, Song JM, Chun BD, Kim YD, Kim UK, et al. Clinical study of correlation between C-terminal cross-linking telopeptide of type I collagen and risk assessment, severity of disease, healing after early surgical intervention in patients with bisphophonate-related osteonecrosis of the jaws. J Korean Assoc Oral Maxillofac Surg 2011;37:1-8. DOI |
7 | Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 2010;141:1365-70. DOI |
8 | Park W, Kim NK, Kim MY, Rhee YM, Kim HJ. Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int 2010;21:527-33. DOI |
9 | Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. DOI |
10 | Hoff A, Toth B, Altundag K, Guarneri V, Adamus A, Nooka A, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24:8528. |
11 | Baqain ZH, Sawair FA, Tamimi Z, Bsoul N, Al Edwan G, Almasad JK, et al. Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl 2010;92:489-94. DOI |
12 | Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62. DOI |
13 | Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-72. |
14 | Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9. DOI |
15 | Suresh E, Pazianas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 2014;53:19-31. DOI |
16 | Park HM, Lee ES, Kim SM. The use of osteoporosis medications in Korea in 2008. Korean J Bone Metab 2009;16;87-93. |
17 | Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47. DOI |
18 | Coleman RE. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast Cancer 2000;7:361-9. DOI |
19 | Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36. DOI |
20 | Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Toni-no RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. DOI |
21 | Silva PG, Ferreira Junior AE, Teofilo CR, Barbosa MC, Lima Junior RC, Sousa FB, et al. Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis. Arch Oral Biol 2015;60:1237-45. DOI |
22 | Miller PD. The kidney and bisphosphonates. Bone 2011;49:77-81. DOI |
23 | Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85. DOI |
24 | Wikipedia: Renal function [Internet]. [place unknown: publisher unknown]. [modified 2017 Feb 1; cited 2016 Sep 8]. Available from: https://en.wikipedia.org/wiki/Renal_function. |
25 | Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. DOI |
26 | Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12. DOI |
27 | Manzano-Moreno FJ, Ramos-Torrecillas J, De Luna-Bertos E, Ruiz C, Garcia-Martinez O. High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. J Craniomaxillofac Surg 2015;43:396-401. DOI |
28 | National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266. DOI |
29 | Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100. DOI |
30 | Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12. DOI |
31 | Park JC, Rhee SH, Kim YH, Kang MS, Son YH, Kim HG, et al. The effectiveness of the surgical approach and drug-holiday on the treatment of bisphosphonate related osteonecrosis of the jaw patient. Int J Oral Maxillofac Surg 2015;44 Suppl 1:e275. |
32 | Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008;74:721-31. DOI |
33 | Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. DOI |
34 | Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. DOI |
35 | Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. J Oral Maxillofac Surg 2014;72:1938-56. DOI |
36 | O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007;18:2758-65. DOI |
37 | Gifre L, Peris P, Monegal A, Martinez-Ferrer A, Hernandez MV, Guanabens N. Effect of bisphosphonates on renal function in patients with osteoporosis. Eur Geriatr Med 2013;4:380-3. DOI |
![]() |